Immunic Therapeutics

August 24, 2020August 24, 2020

1st Healthy Volunteer Dosed in Phase 1 Trial of Potential IBD Treatment IMU-856

News

The first healthy volunteer has been dosed in an Australian Phase 1 clinical trial investigating IMU-856, a potential novel treatment for inflammatory bowel disease (IBD), according to the therapy’s developer Immunic ... Read more

October 9, 2019October 9, 2019

Interim Analysis Suggests Wider-than-expected Dosing Range for IMU-838 to Treat Ulcerative Colitis

News

Interim analysis of a Phase 2 clinical trial that’s investigating IMU-838 in people with ulcerative colitis (UC) suggests a broader dose range than initially anticipated, announced the therapy’s developer, Immunic ... Read more

July 1, 2019July 1, 2019

Therapy Candidate IMU-838 Shows Strong Activity in Preclinical Models of UC, Immunic Announces

News

IMU-838, Immunic Therapeutics‘ lead therapy candidate for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), shows strong activity in cellular and animal models of disease, preclinical studies ... Read more